RecruitingNCT06861673

COCONUT Study Concomitant PVI and LAAC

COnCOmitaNt Pulse Field Ablation Based pUlmonary Vein Isolation and lefT Atrial Appendage Closure - The COCONUT Study


Sponsor

Asklepios proresearch

Enrollment

60 participants

Start Date

Mar 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

In patients with non-valvular AF, at high stroke risk, and who are ineligible for long-term oral anticoagulation LAAC could be an alternative to anticoagulation and safety and efficacy has been shown in several studies and registries.8 While PVI and LAAC are both conducted in the left atrium and share the same access route, a combined concomitant approach might be beneficial for patients but is not conventionally practiced. Due to significantly shorter procedures times and high safety profile PFA based catheter ablation may be advantageous for the combined approach of PVI and LAAC. We are performing a word-wide, retrospective, multicenter registry study focusing on patients with concomitant Farapulse PFA based PVI and LAAC (WATCHMAN Flx, Boston Scientific). To evaluate safety, efficacy and efficiency in a multicenter study the COCONUT study was conducted.


Eligibility

Inclusion Criteria1

  • Indicatio for PVI and LAAC

Exclusion Criteria1

  • Not eligible for any of the procedures PVI and LAAC

Interventions

DEVICEPulmonary vein isolation

concomitant PVI and LAAC


Locations(1)

Asklepios Klinik Altona

Hamburg, Hamburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06861673


Related Trials